Comparative Pharmacology
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN AND AMLODIPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILSPARI versus TELMISARTAN AND AMLODIPINE.
FILSPARI vs TELMISARTAN AND AMLODIPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILSPARI (sparsentan) is an endothelin receptor antagonist (ERA) and angiotensin II receptor blocker (ARB) with high affinity for the endothelin type A (ETA) receptor and angiotensin II type 1 (AT1) receptor. It reduces proteinuria in IgA nephropathy by inhibiting endothelin-1 mediated vasoconstriction, inflammation, and fibrosis, and by blocking angiotensin II mediated effects.
Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to AT1 receptors, causing vasodilation and reduced aldosterone secretion. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium ion influx across vascular smooth muscle and cardiac muscle, leading to peripheral vasodilation and reduced blood pressure.
200 mg orally once daily, with or without food.
Oral: one tablet containing telmisartan 40-80 mg and amlodipine 5-10 mg once daily; maximum dose: telmisartan 80 mg/amlodipine 10 mg daily.
None Documented
None Documented
Terminal half-life ~30 hours in healthy subjects, supporting once-daily dosing.
Telmisartan: terminal half-life ~24 hours (range 20-30 hours), supporting once-daily dosing. Amlodipine: terminal half-life ~30-50 hours (mean 35 hours), achieving steady state after 7-8 days; prolonged half-life allows once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine. ~59% of dose recovered in feces and ~27% in urine as metabolites.
Telmisartan: primarily excreted unchanged in feces (97%) via biliary elimination; renal excretion accounts for <2%. Amlodipine: extensively metabolized in liver; 60% of metabolites excreted renally, 20-25% in feces. Unchanged amlodipine in urine: <10%.
Category C
Category D/X
Endothelin Receptor Antagonist / ARB
ARB